Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation
about
15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammationFactors influencing the eicosanoids synthesis in vivoNew insights into the anti-inflammatory actions of aspirin-induction of nitric oxide through the generation of epi-lipoxinsThe effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosaEffects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infectionPharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disordersA novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties.Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense.Nonsteroidal Anti-Inflammatory Therapy: A Journey Toward Safety.Nitric oxide-releasing aspirin but not conventional aspirin improves healing of experimental colitis.Upregulation of cathepsin W-expressing T cells is specific for autoimmune atrophic gastritis compared to other types of chronic gastritis.Preparation and investigation of acetyl salicylic acid-caffeine complex for rectal administration.Analgesics and Antipyretics
P2860
Q24645794-7C4B4240-FBA7-4004-857E-05475A9A61EEQ28083767-36AFDB11-5095-41C1-8CAD-90DDFE8C2F40Q28180867-ABC41EB8-6DA9-4701-A2F6-655C8E1382C5Q28194351-466569EA-8746-4E21-858F-4A3506BBC18DQ28196516-DA80205D-7103-4969-AA7D-916696D24E83Q28200449-79E0B451-B76C-4625-9CB1-BF4FFBCC4C27Q35831031-F2344362-EA7F-45BD-8C1A-80BD2139A83FQ36075305-AE7B223C-09AE-44C9-89AE-A8BB8EE0C271Q38558587-2705AD66-991E-45BD-B63C-C87345FD1446Q38850732-6CA67BB3-8688-41C8-A8B1-B505C6B724EAQ40820268-947066A0-94F7-4DF0-B214-75DEA2B44765Q42717374-D0044538-06D3-49F9-899B-959C36BC536BQ56113559-D740D306-05F8-49D2-A315-73D8623033C2
P2860
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Aspirin, but not NO-releasing ...... astric damage and inflammation
@ast
Aspirin, but not NO-releasing ...... astric damage and inflammation
@en
Aspirin, but not NO-releasing ...... astric damage and inflammation
@nl
type
label
Aspirin, but not NO-releasing ...... astric damage and inflammation
@ast
Aspirin, but not NO-releasing ...... astric damage and inflammation
@en
Aspirin, but not NO-releasing ...... astric damage and inflammation
@nl
prefLabel
Aspirin, but not NO-releasing ...... astric damage and inflammation
@ast
Aspirin, but not NO-releasing ...... astric damage and inflammation
@en
Aspirin, but not NO-releasing ...... astric damage and inflammation
@nl
P2093
P2860
P356
P1476
Aspirin, but not NO-releasing ...... astric damage and inflammation
@en
P2093
Andrea Mencarelli
John L Wallace
Michael Dicay
Piero del Soldato
Stella R Zamuner
Webb McKnight
P2860
P304
P356
10.1152/AJPGI.00295.2003
P407
P577
2004-01-01T00:00:00Z